Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

3D Printing – A Brave New World For Pharma And Patents

This article was originally published in Scrip

Executive Summary

In the same way that railways and fast broadband access changed the rules on where businesses could operate from, so too will 3D printing change the manufacturing and distribution of tomorrow. It presents enormous opportunity for small and medium businesses and perhaps a chance for manufacturing to return on a larger scale in the most developed economies. The accessibility of 3D printing promises to empower both businesses and individuals to create products which under traditional manufacturing processes would have been prohibitive both in terms of cost and logistics. For businesses of all sizes, the potential to decentralize production holds exciting opportunities. With the first regulatory approval of a 3D printed prescription drug, a world of opportunity presents itself for innovative pharmaceutical companies. However, capitalizing on 3D printing technology whilst retaining control over intellectual property rights (IPRs) will be challenging and require a rethink of traditional approaches both to patent drafting and licensing.

You may also be interested in...



The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy

ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.

US FDA’s 2020 Approvals: A Deep Pipeline, And More Of The Expected

Almost 50 novel agents are already under review at FDA for potential 2020 approval. Candidates are notably diverse, with concentrations in established strongholds (oncology, neuroscience), popular programs (breakthrough), and powerhouse sponsors (keep an eye on Bristol-Myers Squibb right out of the gate).

Gene Therapy Approvals By US FDA Could Double In 2020

CBER is starting the year with four novel gene and cell therapy applications under review and rolling submissions underway for more.

Topics

Related Companies

UsernamePublicRestriction

Register

SC029970

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel